INOVIO PHARMACEUTICALS, INC. Interest Expense
INOVIO PHARMACEUTICALS, INC. (INO) reported Interest Expense of $177.83 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-13
- INOVIO PHARMACEUTICALS, INC. interest expense for the quarter ending 2024-03-31 was $177.83K, a 43.27% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-12-31 was $282.32K, a 9.94% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-09-30 was $313.49K, a 0.00% change year-over-year.
- INOVIO PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-06-30 was $313.49K, a 0.00% change year-over-year.
- INOVIO PHARMACEUTICALS, INC. interest expense for fiscal 2023 was $1.22M, a 2.49% decline from fiscal 2022.
- INOVIO PHARMACEUTICALS, INC. interest expense for fiscal 2022 was $1.25M, a 35.24% decline from fiscal 2021.
- INOVIO PHARMACEUTICALS, INC. interest expense for fiscal 2021 was $1.94M, a 77.75% decline from fiscal 2020.
- INOVIO PHARMACEUTICALS, INC. interest expense for fiscal 2020 was $8.70M, a 9.48% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $177.83K 10-Q · filed 2024-05-13 | $460.16K derived: sum of 2 quarters · filed 2024-05-13 | $773.65K derived: sum of 3 quarters · filed 2024-05-13 | $1.09M derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | $282.32K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $595.81K derived: sum of 2 quarters · filed 2024-03-06 | $909.30K derived: sum of 3 quarters · filed 2024-03-06 | $1.22M 10-K · filed 2024-03-06 |
| 2023-09-30 | $313.49K 10-Q · filed 2023-11-09 | $626.98K derived: sum of 2 quarters · filed 2023-11-09 | $940.46K 10-Q · filed 2023-11-09 | $1.25M derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-06-30 | $313.49K 10-Q · filed 2023-08-09 | $626.98K 10-Q · filed 2023-08-09 | $940.46K derived: sum of 3 quarters · filed 2024-05-13 | $1.25M derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-03-31 | $313.49K 10-Q · filed 2024-05-13 | $626.98K derived: sum of 2 quarters · filed 2024-05-13 | $940.46K derived: sum of 3 quarters · filed 2024-05-13 | $1.25M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $313.49K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $626.98K derived: sum of 2 quarters · filed 2024-03-06 | $940.46K derived: sum of 3 quarters · filed 2024-03-06 | $1.25M 10-K · filed 2024-03-06 |
| 2022-09-30 | $313.49K 10-Q · filed 2023-11-09 | $626.98K derived: sum of 2 quarters · filed 2023-11-09 | $940.46K 10-Q · filed 2023-11-09 | $1.42M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $313.49K 10-Q · filed 2023-08-09 | $626.98K 10-Q · filed 2023-08-09 | $1.11M derived: sum of 3 quarters · filed 2024-03-06 | $1.58M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $313.49K 10-Q · filed 2023-05-10 | $793.80K derived: sum of 2 quarters · filed 2024-03-06 | $1.27M derived: sum of 3 quarters · filed 2024-03-06 | $1.74M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $480.31K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $956.69K derived: sum of 2 quarters · filed 2024-03-06 | $1.42M derived: sum of 3 quarters · filed 2024-03-06 | $1.94M 10-K · filed 2024-03-06 |
| 2021-09-30 | $476.37K 10-Q · filed 2022-11-08 | $943.10K derived: sum of 2 quarters · filed 2022-11-08 | $1.46M 10-Q · filed 2022-11-08 | $2.52M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $466.73K 10-Q · filed 2022-08-09 | $979.76K 10-Q · filed 2022-08-09 | $2.05M derived: sum of 3 quarters · filed 2022-08-09 | $4.03M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $513.03K 10-Q · filed 2022-05-10 | $1.58M derived: sum of 2 quarters · filed 2022-05-10 | $3.57M derived: sum of 3 quarters · filed 2022-05-10 | $6.41M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $1.07M 10-K · filed 2021-03-01 | $3.05M derived: sum of 2 quarters · filed 2021-11-09 | $5.90M derived: sum of 3 quarters · filed 2021-11-09 | $8.70M 10-K · filed 2023-03-01 |
| 2020-09-30 | $1.98M 10-Q · filed 2021-11-09 | $4.83M derived: sum of 2 quarters · filed 2021-11-09 | $7.63M 10-Q · filed 2021-11-09 | $10.30M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $2.85M 10-Q · filed 2021-08-09 | $5.65M 10-Q · filed 2021-08-09 | $8.32M derived: sum of 3 quarters · filed 2021-08-09 | $10.75M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $2.80M 10-Q · filed 2021-05-10 | $5.47M derived: sum of 2 quarters · filed 2021-05-10 | $7.90M derived: sum of 3 quarters · filed 2021-05-10 | $10.10M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $2.67M 10-K · filed 2021-03-01 | $5.10M derived: sum of 2 quarters · filed 2021-03-01 | $7.29M derived: sum of 3 quarters · filed 2021-03-01 | $7.95M 10-K · filed 2022-03-01 |
| 2019-09-30 | $2.43M 10-K · filed 2021-03-01 | $4.62M derived: sum of 2 quarters · filed 2021-03-01 | $5.28M 10-Q · filed 2020-11-09 | $5.28M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $2.19M 10-K · filed 2021-03-01 | $2.85M 10-Q · filed 2020-08-10 | $2.85M derived: sum of 3 quarters · filed 2021-03-01 | $2.85M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $656.25K 10-K · filed 2021-03-01 | $656.25K derived: sum of 2 quarters · filed 2021-03-01 | $656.25K derived: sum of 3 quarters · filed 2021-03-01 | $656.25K derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $25.93K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |